zinc - sidp - home mahon… · tolerable upper intake levels: • n / v / d • ↓ appetite •...

19
Zinc Monica V. Mahoney, PharmD, BCPS AQ-ID, BCIDP Clinical Pharmacy Specialist, Beth Israel Deaconess Medical Center [email protected] @mmPharmD A Review of Pertinent Drug Information for SARS-CoV-2 Data as of May 3, 2020

Upload: others

Post on 22-Oct-2020

1 views

Category:

Documents


0 download

TRANSCRIPT

  • Zinc

    Monica V. Mahoney, PharmD, BCPS AQ-ID, BCIDPClinical Pharmacy Specialist, Beth Israel Deaconess Medical Center

    [email protected]@mmPharmD

    A Review of Pertinent Drug Information for SARS-CoV-2

    Data as of May 3, 2020

  • Zinc Chemistry & Metabol ism• Trace element

    • Cellular metabolism:• Required for catalytic activity of ~100 enzymes• Immune function• Protein synthesis• Wound healing• DNA synthesis• Cell division

    National Institutes of Health. Zinc Fact Sheet. https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/

    https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/

  • Zinc

    National Institutes of Health. Zinc Fact Sheet. https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/

    Doses & Toxicity

    Age Male Female

    0-6 months 2 mg 2 mg

    7-12 months 3 mg 3 mg

    1-3 years 3 mg 3 mg

    4-8 years 5 mg 5 mg

    9-13 years 8 mg 8 mg

    14-18 years 11 mg 9 mg

    19+ years 11 mg 8 mg

    Recommended Daily Intake:Age Male Female

    0-6 months 4 mg 4 mg

    7-12 months 5 mg 5 mg

    1-3 years 7 mg 7 mg

    4-8 years 12 mg 12 mg

    9-13 years 23 mg 23 mg

    14-18 years 34 mg 34 mg

    19+ years 40 mg 40 mg

    Tolerable Upper Intake Levels:

    • N / V / D• ↓ appetite• Abdominal cramping• Headaches• ↓ copper levels• Altered iron function• ↓ immune function

    https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/

  • Zinc Salts

    Zinc acetate … 2.8 mgZinc gluconate … 7.14 mg

    Zinc sulfate ….4.4 mg

    Equivalent to 1 mg elemental zinc …

    Common Zinc Salt Products• Zinc gluconate lozenge … 13.3 mg elemental zinc• Zinc sulfate 220 mg … 50 mg elemental zinc

    www.pdr.net/drug-summary/Galzin-zinc-acetate-3863 Accessed 5/5/20

    http://www.pdr.net/drug-summary/Galzin-zinc-acetate-3863

  • Population Intervention Infection Types

    49 elderly

    patients

    45 mg zinc/day

    vs.Placebo

    Results

    Prasad AS, et al. Am J Cin Nutr 2007;85:837-44

    Zinc & Infectious Diseases

    Infection rate:

    29% vs. 88%

    • Cold• URI• Fever• Flu

    12-month placebo-controlled trial:

  • Zinc & the Common Cold

    Hemila H. J Royal Society Med Open. 2017;8:1-7. https://doi.org/10.1177/2054270417694291

    Meta-analysis comparing zinc lozenges ≥75 mg/day to treat cold symptoms

    SALT :acetate = gluconate

    DAILY DOSE :100 mg

    LOZENGE DOSE & FREQUENCY:Too heterogeneous

    Reduction in duration by 33%

    https://doi.org/10.1177/2054270417694291

  • Rhinovirus

    Influenza

    Adenovirus

    Parainfluenza

    RSV

    Enterovirus

    Coronavirus

    The Common Cold

    Makela MJ et al. J Clin Microbiol. 1998;36:539-42

  • Zinc & SARS-CoV

    te Velthuis AJW, et al. PLoS Pathogens. 2010;6:e1001176. https://doi.org/10.1371/journal.ppat.1001176

    • Pyrithione (PT): zinc ionophore• Transports zinc intracellularly

    • ↑ zinc via ↑ PT = Ø replication of SARS-CoV• RNA synthesis catalyzed by an RNA-dependent

    RNA polymerase (RdRp)• Ø RdRp elongation• ↓ template binding

    ↑ PT ↓ green-fluorescent protein-marked SARS-CoV. Blue = 0 µM; green = 1 µM; black = 2 µM ZnOAC2

    https://doi.org/10.1371/journal.ppat.1001176

  • Zinc & Chloroquine

    Xue J, et al. PLoS ONE. 2014;9:e109180. https://doi.org/10.1371/journal.pone.0109180

    • Chloroquine enhanced intracellular zinc uptake

    • Zinc enhanced cytotoxic activity of chloroquine

    https://doi.org/10.1371/journal.pone.0109180

  • Proposed Mechanisms of Action

    Skalny AV, et al. Intern J Molecular Med. 2020. https://doi.org/10.3892/ijmm.2020.4575

    https://doi.org/10.3892/ijmm.2020.4575

  • www.clinicaltrials.gov Accessed: 5/3/20

    Tr e a t m e n t : P r o p h y l a x i s :

    Current Zinc-COVID-19 Trials

    NCT04370782• HCQ• Azithromycin• Zinc

    • HCQ• Doxycycline• Zinc

    NCT04342728• Zinc

    • Zinc• Vitamin C

    • Vitamin C

    • SOC

    NCT04351490• Zinc• Vitamin D3

    • SOC

    NCT04334512• HCQ• Azithromycin• Vitamin C• Vitamin D• Zinc

    NCT04335084• HCQ• Vitamin C• Vitamin D• Zinc

    NCT04326725• HCQ• Vitamin C• Zinc

    http://www.clinicaltrials.gov/

  • Zinc: COVID-19 Treatment

    NCT04370782• HCQ 400mg BID x 2 then 200mg BID days 2-5• Azithromycin 500mg x1 then 250mg days 2-5• Zinc sulfate 220mg daily x 5 days

    • HCQ 400mg BID x 2 then 200mg BID days 2-5• Doxycycline 200mg daily x 5 days• Zinc sulfate 220mg daily x 5 days

    • Randomized, open-label, outpatient treatment. 1˚ outcome = time to symptom resolution

    NCT04334512 (HAZDpaC)• HCQ dose unknown• Azithromycin dose unknown• Vitamin C dose unknown• Vitamin D dose unknown• Zinc salt and dose unknown

    • Open-label, single arm treatment. 1˚ outcome = successful treatment at 24 weeks

    www.clinicaltrials.gov Accessed: 5/3/20

    http://www.clinicaltrials.gov/

  • Zinc: COVID-19 Treatment

    NCT04351490 (ZnD3-CoVici)• Zinc gluconate 15 mg BID x 2 months• Vitamin D3 2000 IU daily x 2 months

    • SOC

    • Randomized, open-label inpatient treatment ≥60 years. 1˚ outcome = survival rate in asymptomaticpatients at inclusion

    NCT04342728 (COVIDAtoZ)• Zinc gluconate 50 mg qHS x 10 days

    • Zinc gluconate 50 mg qHS x 10 days• Vitamin C 8000 mg/day ÷ 2-3 doses with food x 10d

    • Vitamin C 8000 mg/day ÷ 2-3 doses with food x 10d

    • SOC

    • Open-label treatment. 1˚ outcome = time to symptom resolution

    www.clinicaltrials.gov Accessed: 5/3/20

    http://www.clinicaltrials.gov/

  • Zinc: COVID-19 Prophylaxis

    NCT04335084 (HELPCOVID-19)• HCQ dose unknown• Vitamin C dose unknown• Vitamin D dose unknown• Zinc salt and dose unknown

    • Open-label prophylaxis of healthcare workers at risk for COVID-19. 1˚ outcome = prevention of COVID-19 at 24 weeks via diary symptom tracking.

    NCT04326725• HCQ 200 mg x1, every 3 weeks• Vitamin C dose unknown daily• Zinc salt and dose unknown daily

    • Case-control prophylaxis of healthcare workers. 1˚ outcome = protection against COVID-19 at 4 months.

    www.clinicaltrials.gov Accessed: 5/3/20

    http://www.clinicaltrials.gov/

  • Zinc

    National Institutes of Health. Zinc Fact Sheet. https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/

    Doses & Toxicity

    Age Male Female

    0-6 months 2 mg 2 mg

    7-12 months 3 mg 3 mg

    1-3 years 3 mg 3 mg

    4-8 years 5 mg 5 mg

    9-13 years 8 mg 8 mg

    14-18 years 11 mg 9 mg

    19+ years 11 mg 8 mg

    Recommended Daily Intake:Age Male Female

    0-6 months 4 mg 4 mg

    7-12 months 5 mg 5 mg

    1-3 years 7 mg 7 mg

    4-8 years 12 mg 12 mg

    9-13 years 23 mg 23 mg

    14-18 years 34 mg 34 mg

    19+ years 40 mg 40 mg

    Tolerable Upper Intake Levels:

    • N / V / D• ↓ appetite• Abdominal cramping• Headaches• ↓ copper levels• Altered iron function• ↓ immune function

    https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/

  • • Zinc is a polyvalent cation – caution with oral co-administration

    • HIV medications: bictegravir, dolutegravir, elvitegravir, raltegravir• Antibiotics: quinolones, tetracyclines

    • Diuretics: (chlorthalidone, hydrochlorothiazide) may ↑ urinary zinc excretion

    • ↑ iron may ↓ zinc• ↑ zinc may ↓ copper

    National Institutes of Health. Zinc Fact Sheet. https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/

    Zinc Drug Interactions

    https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/

  • COVID-19 Guidel ines

    Accessed: 5/3/20

    Guideline Zinc CitationIDSA (Infectious Diseases Society of America)

    No mention https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/

    NIH (National Institutes of Health) No mention https://covid19treatmentguidelines.nih.gov/introduction/

    WHO (World Health Organization) No mention https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected

    SCCM (Society of Critical Care Medicine – Surviving Sepsis Campaign)

    No mention https://www.sccm.org/getattachment/Disaster/SSC-COVID19-Critical-Care-Guidelines.pdf?lang=en-US

    NICE (National Institute for Health and Care Excellence)

    No mention https://www.nice.org.uk/covid-19

    https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/https://covid19treatmentguidelines.nih.gov/introduction/https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspectedhttps://www.sccm.org/getattachment/Disaster/SSC-COVID19-Critical-Care-Guidelines.pdf?lang=en-UShttps://www.nice.org.uk/covid-19

  • Summary• Data support zinc treatment of the common cold

    • Data currently lacking in zinc for COVID-19

    • Ongoing trials:• Treatment: most studying in combination therapy• Prophylaxis: only studying in combination therapy

    • Not mentioned in national treatment guidelines

  • Zinc

    Monica V. Mahoney, PharmD, BCPS AQ-ID, BCIDPClinical Pharmacy Specialist, Beth Israel Deaconess Medical Center

    [email protected]@mmPharmD

    A Review of Pertinent Drug Information for SARS-CoV-2

    Data as of May 3, 2020

    Slide Number 1Slide Number 2Slide Number 3Slide Number 4Slide Number 5Slide Number 6Slide Number 7Slide Number 8Slide Number 9Slide Number 10Slide Number 11Slide Number 12Slide Number 13Slide Number 14Slide Number 15Slide Number 16Slide Number 17Slide Number 18Slide Number 19